Eli Lilly Buys Ventyx for $1.2B, Expanding NLRP3 Drug Portfolio

Eli Lilly buys Ventyx as it builds its infiltration in inflammation-related diseases. The Indianapolis-based pharma giant reported today that it has initiated into a final deal to acquire Ventyx Biosciences.

Ventyx Biosciences is a San Diego biopharmaceutical firm in the clinical stage specializing in oral therapy of inflammatory-mediated diseases.

The purchase expands a small-molecule drug pipeline of Lilly with a growing range of clinical-stage NLRP3 inhibitors by Ventyx. The aim of these assets is to treat chronic inflammation associated with cardiometabolic diseases, neurodegenerative diseases, and immune-related diseases, where treatment options are limited and the need is high.

Also Read: Cost-Effectiveness of Minimally Invasive Surgery in Outpatient Settings

There is increasing evidence that inflammation is a key driver of many chronic diseases," said Daniel M. Skovronsky, Chief Scientific and Product Officer, and President of Lilly Research Laboratories. "Ventyx's clinical-stage pipeline addresses a critical need for better treatment options across diseases …advances for patients living with challenging diseases across focus areas of cardiometabolic health, neurodegeneration and autoimmunity."

"Our portfolio of class-leading NLRP3 inhibitors modulate residual and chronic inflammation that is now recognized as a major risk factor in a host of neuroinflammatory, cardiometabolic and cardiovascular diseases," said Raju Mohan, Chief Executive Officer of Ventyx Biosciences.

According to the agreement, Eli Lilly will purchase Ventyx at a price of 14.00 per share in cash and the purchase would give the company a value of about 1.2 billion. The deal does not require financing, and should be concluded during the first half of 2026, as long as shareholders and regulators approve.